abstract |
Human insulin analogues having a positively charged amino acid residue, i.e. Lys or Arg, in position B28, further being modified in the C-terminal end of the B-chain from PheB24 to the C-terminal amino acid residue and wherein A18, A21 and/or B3 is different from Asn as well as insulin preparations containing the human insulin analogues are provided. |